Christopher J Lord

List of Publications by Citations

206 papers	26,205 citations	75 h-index	160 g-index
230 ext. papers	31,174 ext. citations	13.2 avg, IF	7.21 L-index

#	Paper	IF	Citations
206	Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **2005**, 434, 917-21	50.4	4468
205	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2015**, 373, 1697-708	59.2	1345
204	The DNA damage response and cancer therapy. *Nature*, **2012**, 481, 287-94	50.4	1118
203	PARP inhibitors: Synthetic lethality in the clinic. *Science*, **2017**, 355, 1152-1158	33.3	1107
202	Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. *Cancer Research*, **2006**, 66, 8109-15	10.1	969
201	Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer*, **2011** , 11, 719-25	31.3	893
200	Resistance to therapy caused by intragenic deletion in BRCA2. *Nature*, **2008**, 451, 1111-5	50.4	741
199	BRCAness revisited. *Nature Reviews Cancer*, **2016**, 16, 110-20	31.3	678
198	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. *EMBO Molecular Medicine*, **2009**, 1, 315-22	12	500
197	Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nature Genetics*, **2011**, 43, 879-882	36.3	379
196	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. *Cancer Research*, **2016**, 76, 2301-13	10.1	344
195	BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. *Clinical Cancer Research*, **2013**, 19, 5003-15	12.9	327
194	Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annual Review of Medicine*, **2015**, 66, 455-70	17.4	320
193	Genetic interactions in cancer progression and treatment. *Cell*, **2011**, 145, 30-8	56.2	304
192	Mechanisms of resistance to therapies targeting BRCA-mutant cancers. *Nature Medicine*, **2013**, 19, 1381-8	30.5	300
191	The shieldin complex mediates 53BP1-dependent DNA repair. *Nature*, **2018**, 560, 117-121	50.4	277
190	A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. *EMBO Journal*, **2008**, 27, 1368-77	13	257

189	Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Science Translational Medicine*, **2011**, 3, 98ra82	17.5	252
188	A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. *Clinical Cancer Research*, **2010**, 16, 6159-68	12.9	240
187	Targeted therapy for cancer using PARP inhibitors. *Current Opinion in Pharmacology*, **2008**, 8, 363-9	5.1	237
186	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. *Journal of Pathology*, **2013**, 229, 422-9	9.4	235
185	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. *Cancer Discovery*, **2017**, 7, 1006-1017	24.4	232
184	Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. *Cancer Discovery*, **2013**, 3, 512-9	24.4	213
183	Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. *Cancer Research*, **2014**, 74, 287-97	10.1	212
182	The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. *Molecular Cell*, **2008**, 29, 451-64	17.6	212
181	Utilizing RNA interference to enhance cancer drug discovery. *Nature Reviews Drug Discovery*, **2007**, 6, 556-68	64.1	211
180	Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. *Blood*, **2012**, 120, 1077-86	2.2	200
179	Synthetic lethal therapies for cancer: what's next after PARP inhibitors?. *Nature Reviews Clinical Oncology*, **2018**, 15, 564-576	19.4	199
178	Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. *Nature Reviews Drug Discovery*, **2012**, 11, 923-36	64.1	196
177	Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. *Nature*, **2013**, 493, 406-10	50.4	191
176	PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. *Science Translational Medicine*, **2010**, 2, 53ra75	17.5	190
175	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. *Nature Communications*, **2018**, 9, 1849	17.4	189
174	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. *Nature Communications*, **2016**, 7, 13837	17.4	184
173	Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. *Cancer Cell*, **2008**, 13, 91-104	24.3	177
172	Mismatch repair deficient colorectal cancer in the era of personalized treatment. *Nature Reviews Clinical Oncology*, **2010**, 7, 197-208	19.4	165

171	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of Reversion Mutations Associated with Resistance to PARP Inhibitors. *Cancer Discovery*, **2017**, 7, 999-1005	24.4	158
170	DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. *Cancer Cell*, **2010**, 17, 235-48	24.3	158
169	DNA repair deficiency as a therapeutic target in cancer. *Current Opinion in Genetics and Development*, **2008**, 18, 80-6	4.9	144
168	p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. *EMBO Reports*, **2006**, 7, 219-24	6.5	143
167	The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. *Immunity*, **2000**, 13, 107-15	32.3	143
166	Sequential interactions with Sec23 control the direction of vesicle traffic. *Nature*, **2011**, 473, 181-6	50.4	142
165	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. *Journal of Clinical Investigation*, **2019**, 129, 1211-1228	15.9	139
164	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. *Clinical Cancer Research*, **2009**, 15, 2711-22	12.9	138
163	Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. *EMBO Molecular Medicine*, **2009**, 1, 323-37	12	138
162	A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. *DNA Repair*, **2008**, 7, 2010-9	4.3	134
161	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. *Breast Cancer Research and Treatment*, **2010**, 121, 575-89	4.4	132
160	PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. *Clinical Cancer Research*, **2009**, 15, 2269-80	12.9	128
159	Whole genome sequencing of matched primary and metastatic acral melanomas. *Genome Research*, **2012**, 22, 196-207	9.7	126
158	A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. *PLoS ONE*, **2013**, 8, e61520	3.7	123
157	BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. *Cancer Biology and Therapy*, **2005**, 4, 934-6	4.6	123
156	Structural basis for recruitment of BRCA2 by PALB2. *EMBO Reports*, **2009**, 10, 990-6	6.5	121
155	Functional viability profiles of breast cancer. *Cancer Discovery*, **2011**, 1, 260-73	24.4	117
154	PARP inhibitor combination therapy. *Critical Reviews in Oncology/Hematology*, **2016**, 108, 73-85	7	116

153	Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. *Genome Research*, **2000**, 10, 446-53	9.7	112
152	Therapeutic targeting of the DNA mismatch repair pathway. *Clinical Cancer Research*, **2010**, 16, 5107-13	12.9	110
151	Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. *Clinical Cancer Research*, **2013**, 19, 5485-93	12.9	103
150	DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. *EMBO Reports*, **2004**, 5, 989-93	6.5	98
149	Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2730-5	11.5	96
148	High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. *Genome Biology*, **2011**, 12, R104	18.3	89
147	Structural basis for allosteric PARP-1 retention on DNA breaks. *Science*, **2020**, 368,	33.3	87
146	Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. *Molecular Cancer Therapeutics*, **2006**, 5, 209-18	6.1	87
145	Searching for synthetic lethality in cancer. *Current Opinion in Genetics and Development*, **2011**, 21, 34-41	4.9	86
144	Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. *EMBO Molecular Medicine*, **2012**, 4, 1087-96	12	85
143	Integrated functional, gene expression and genomic analysis for the identification of cancer targets. *PLoS ONE*, **2009**, 4, e5120	3.7	85
142	Targeting the double-strand DNA break repair pathway as a therapeutic strategy. *Clinical Cancer Research*, **2006**, 12, 4463-8	12.9	85
141	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. *Nature Genetics*, **2012**, 44, 1182-4	36.3	84
140	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. *Journal of Clinical Investigation*, **2018**, 128, 4441-4453	15.9	84
139	The highly conserved COPII coat complex sorts cargo from the endoplasmic reticulum and targets it to the golgi. *Cold Spring Harbor Perspectives in Biology*, **2013**, 5,	10.2	80
138	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. *Nature Reviews Clinical Oncology*, **2012**, 9, 144-55	19.4	79
137	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. *Nature Medicine*, **2018**, 24, 1204-1215	50.5	79
136	MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA. *Neuro-Oncology*, **2020**, 22, iii407-iii408	1	78

135	Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. *Cell Reports*, **2016**, 14, 2490-501	10.6	77
134	A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. *Oncogene*, **2008**, 27, 1036-44	9.2	77
133	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. *Cancer Discovery*, **2015**, 5, 488-505	24.4	76
132	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. *Journal of Pathology*, **2014**, 232, 553-65	9.4	75
131	Synthetic lethal approaches to breast cancer therapy. *Nature Reviews Clinical Oncology*, **2010**, 7, 718-24	19.4	75
130	Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. *Cancer Research*, **2011**, 71, 1836-48	10.1	72
129	Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation. *Nucleic Acids Research*, **2012**, 40, 7190-206	20.1	72
128	A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. *Oncogene*, **2013**, 32, 5377-87	9.2	71
127	The genomic profile of HER2-amplified breast cancers: the influence of ER status. *Journal of Pathology*, **2008**, 216, 399-407	9.4	69
126	Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. *Cancer Discovery*, **2019**, 9, 230-247	24.4	67
125	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. *Cell Reports*, **2018**, 23, 2107-2118	10.6	67
124	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. *Journal of Clinical Oncology*, **2020**, 38, 3195-3204	2.2	63
123	Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?. *Cytokine*, **2000**, 12, 477-82	4	62
122	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. *British Journal of Cancer*, **2017**, 117, 113-123	8.7	59
121	Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. *Oncogene*, **2009**, 28, 1465-70	9.2	57
120	Directing the use of DDR kinase inhibitors in cancer treatment. *Expert Opinion on Investigational Drugs*, **2017**, 26, 1341-1355	5.9	57
119	An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. *Cancer Discovery*, **2014**, 4, 304-17	24.4	55
118	A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. *Breast Cancer Research and Treatment*, **2009**, 118, 481-98	4.4	55

117	Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. *Molecular Cancer Therapeutics*, **2016**, 15, 1472-84	6.1	54
116	Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. *Breast Cancer Research and Treatment*, **2012**, 135, 505-17	4.4	54
115	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. *Annals of Oncology*, **2013**, 24, 1416-8	10.3	54
114	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. *Modern Pathology*, **2010**, 23, 1334-45	9.8	54
113	Statistical modeling of interlocus interactions in a complex disease: rejection of the multiplicative model of epistasis in type 1 diabetes. *Genetics*, **2001**, 158, 357-67	4	54
112	Identification of miRNA modulators to PARP inhibitor response. *DNA Repair*, **2013**, 12, 394-402	4.3	52
111	Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. *Stem Cells*, **2012**, 30, 1338-48	5.8	52
110	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. *Cancer Discovery*, **2018**, 8, 498-515	24.4	51
109	APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. *EMBO Journal*, **2012**, 31, 1160-76	13	51
108	Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. *EMBO Molecular Medicine*, **2010**, 2, 130-42	12	51
107	Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress. *Nucleic Acids Research*, **2014**, 42, 6270-85	20.1	50
106	Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. *Biochemical Journal*, **2009**, 417, 361-70	3.8	50
105	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. *PLoS ONE*, **2016**, 11, e0149099	3.7	47
104	Genomic instability and the selection of treatments for cancer. *Journal of Pathology*, **2010**, 220, 281-9	9.4	46
103	Mapping by genetic interaction: high-resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse. *Diabetes*, **2001**, 50, 2633-7	0.9	46
102	Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. *Oncogene*, **2011**, 30, 4243-60	7.6	45
101	Modeling Therapy Resistance in -Mutant Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 2022-2034	6.1	44
100	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *Journal of Pathology*, **2012**, 227, 29-41	9.4	44

99	The proteasome is involved in determining differential utilization of double-strand break repair pathways. *Oncogene*, **2007**, 26, 7601-6	9.2	44
98	Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. *Journal of Cell Biology*, **2019**, 218, 3827-3844	7.3	43
97	Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. *British Journal of Cancer*, **2010**, 103, 1192-200	8.7	43
96	Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. *Molecular Cancer Therapeutics*, **2015**, 14, 865-76	6.1	42
95	Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. *Breast Cancer Research and Treatment*, **2012**, 135, 79-91	4.4	42
94	Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. *Oncogene*, **2014**, 33, 966-76	9.2	41
93	Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1824-36	6.1	40
92	The derivation of highly germline-competent embryonic stem cells containing NOD-derived genome. *Diabetes*, **2003**, 52, 205-8	0.9	40
91	Clinical Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. *Cancer Discovery*, **2020**, 10, 1475-1488	24.4	38
90	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers. *Cancer Discovery*, **2020**, 10, 1528-1543	24.4	37
89	Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. *Cell Reports*, **2018**, 22, 1185-1199	10.6	37
88	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 306-315	6.1	37
87	De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability Syndrome. *American Journal of Human Genetics*, **2017**, 100, 650-658	11	36
86	Genomic characterisation of acral melanoma cell lines. *Pigment Cell and Melanoma Research*, **2012**, 25, 488-92	4.5	35
85	High-throughput RNAi screening reveals novel regulators of telomerase. *Cancer Research*, **2011**, 71, 3328-40	8.4	35
84	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
83	Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. *BMC Medical Genomics*, **2011**, 4, 75	3.7	33
82	The promise of combining inhibition of PI3K and PARP as cancer therapy. *Cancer Discovery*, **2012**, 2, 982-4	24.4	33

81	Sit4p/PP6 regulates ER-to-Golgi traffic by controlling the dephosphorylation of COPII coat subunits. *Molecular Biology of the Cell*, **2013**, 24, 2727-38	3.5	32
80	Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. *Molecular Cell*, **2021**, 81, 767-783.e11	17.6	32
79	The genomic landscape of oesophagogastric junctional adenocarcinoma. *Journal of Pathology*, **2013** , 231, 301-10	9.4	31
78	Biology-driven cancer drug development: back to the future. *BMC Biology*, **2010**, 8, 38	7.3	30
77	Pol□inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. *Nature Communications*, **2021**, 12, 3636	17.4	30
76	ADP-ribosyltransferases, an update on function and nomenclature. *FEBS Journal*, **2021**,	5.7	30
75	ATR Is a Therapeutic Target in Synovial Sarcoma. *Cancer Research*, **2017**, 77, 7014-7026	10.1	29
74	Functional characterization of EMSY gene amplification in human cancers. *Journal of Pathology*, **2011**, 225, 29-42	9.4	29
73	Synthetic Lethality and Cancer - Penetrance as the Major Barrier. *Trends in Cancer*, **2018**, 4, 671-683	12.5	29
72	A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. *Scientific Reports*, **2019**, 9, 201	4.9	28
71	Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. *Journal of Pathology: Clinical Research*, **2018**, 4, 154-166	5.3	28
70	Targeting the DNA damage response in immuno-oncology: developments and opportunities. *Nature Reviews Cancer*, **2021**, 21, 701-717	31.3	28
69	A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events. *Cell Systems*, **2017**, 5, 399-409.e5	10.6	27
68	Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. *Journal of Pathology*, **2009**, 219, 306-16	9.4	27
67	Functional analysis of Drosophila melanogaster BRCA2 in DNA repair. *DNA Repair*, **2008**, 7, 10-9	4.3	27
66	Phenotypic effects of heterozygosity for a BRCA2 mutation. *Human Molecular Genetics*, **2003**, 12, 2645-56	5.6	27
65	Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes. *Cancer Research*, **2017**, 77, 4279-4292	10.1	26
64	Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. *British Journal of Cancer*, **2013**, 108, 983-92	8.7	26

63	Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer. *Nature*, **2020**, 585, 447-452	50.4	26
62	Identification of a structurally distinct CD101 molecule encoded in the 950-kb Idd10 region of NOD mice. *Diabetes*, **2003**, 52, 1551-6	0.9	25
61	Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells. *Journal of Pathology*, **2016**, 239, 197-205	9.4	25
60	Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. *Journal of Pathology*, **2016**, 240, 315-328	9.4	24
59	Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. *Breast Cancer Research*, **2007**, 9, R85	8.3	24
58	A modified method for whole exome resequencing from minimal amounts of starting DNA. *PLoS ONE*, **2012**, 7, e32617	3.7	24
57	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. *European Urology*, **2021**, 79, 200-211	10.2	24
56	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer*, **2019**, 125, 1963-1972	6.4	22
55	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. *Cancer Research*, **2021**, 81, 2888-2902	10.1	22
54	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. *Oncogene*, **2014**, 33, 619-31	9.2	21
53	Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. *Cancer Research*, **2014**, 74, 5866-77	10.1	20
52	The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling. *Oncotarget*, **2014**, 5, 12126-40	3.3	20
51	Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. *Oncogene*, **2018**, 37, 5701-5718	9.2	19
50	Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. *Molecular Cancer Therapeutics*, **2013**, 12, 2135-44	6.1	19
49	NLK is a novel therapeutic target for PTEN deficient tumour cells. *PLoS ONE*, **2012**, 7, e47249	3.7	19
48	Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma. *Cancer Research*, **2017**, 77, 4517-4529	10.1	18
47	Dissecting PARP inhibitor resistance with functional genomics. *Current Opinion in Genetics and Development*, **2019**, 54, 55-63	4.9	17
46	First-line PARP inhibition in ovarian cancer - standard of care for all?. *Nature Reviews Clinical Oncology*, **2020**, 17, 136-137	19.4	16

45	Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. *Journal of Pathology*, **2011**, 224, 309-21	9.4	16
44	Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. *PLoS ONE*, **2011**, 6, e21639	3.7	16
43	Beyond DNA repair: the novel immunological potential of PARP inhibitors. *Molecular and Cellular Oncology*, **2019**, 6, 1585170	1.2	15
42	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. *Gut*, **2018**, 67, 1780-1792	19.2	15
41	Bringing DNA repair in tumors into focus. *Clinical Cancer Research*, **2009**, 15, 3241-3	12.9	15
40	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. *Cancer Discovery*, **2021**, 11, 2812-2827	24.4	15
39	A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. *Molecular Cancer Therapeutics*, **2019**, 18, 204-212	6.1	14
38	DAISY: picking synthetic lethals from cancer genomes. *Cancer Cell*, **2014**, 26, 306-308	24.3	13
37	An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. *BMC Genomics*, **2011**, 12, 355	4.5	13
36	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. *Journal of Clinical Investigation*, **2018**, 128, 1671-1687	15.9	13
35	Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. *Oncotarget*, **2015**, 6, 10746-58	3.3	13
34	Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. *EBioMedicine*, **2020**, 59, 102971	8.8	13
33	Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets. *Nature Communications*, **2018**, 9, 2016	17.4	13
32	Synthetic lethality: the road to novel therapies for breast cancer. *Endocrine-Related Cancer*, **2016**, 23, T39-55	5.7	12
31	RNA interference screening demystified. *Journal of Clinical Pathology*, **2009**, 62, 195-200	3.9	12
30	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. *Oncotarget*, **2015**, 6, 10994-1008	3.3	12
29	Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. *ELife*, **2020**, 9,	8.9	12
28	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells. *Scientific Data*, **2017**, 4, 170020	8.2	11

27	Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. *Journal of Pathology*, **2015**, 236, 186-200	9.4	11
26	CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. *Carcinogenesis*, **2009**, 30, 1696-701	4.6	11
25	HLA-B*5603: sequence of a novel hybrid allele comprising B*56 and B*4601 segments. *Tissue Antigens*, **1997**, 49, 496-8		11
24	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. *Scientific Reports*, **2018**, 8, 10614	4.9	9
23	Translational genomics of ovarian clear cell carcinoma. *Seminars in Cancer Biology*, **2020**, 61, 121-131	12.7	9
22	Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors. *MedChemComm*, **2015**, 6, 1687-1692	5	8
21	The murine type 1 diabetes loci, Idd1, Idd3, Idd5, Idd9, and Idd17/10/18, do not control thymic CD4-CD8-/TCRalphabeta+ deficiency in the nonobese diabetic mouse. *Mammalian Genome*, **2001**, 12, 175-6	3.2	8
20	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.. *Nature Cell Biology*, **2022**,	23.4	7
19	MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. *Oncotarget*, **2020**, 11, 2141-2159	3.3	7
18	Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. *Journal of Biological Chemistry*, **2016**, 291, 16686-98	5.4	7
17	Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. *Cancer Discovery*, **2018**, 8, 272-275	24.4	4
16	CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. *Cell Systems*, **2017**, 5, 82-86.e3	10.6	4
15	Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. *Journal of Pathology: Clinical Research*, **2020**, 6, 3-11	5.3	4
14	ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). *International Journal of Gynecological Cancer*, **2021**, 31, 1471-1475	3.5	4
13	PARP inhibitors and breast cancer: highlights and hang-ups. *Expert Review of Precision Medicine and Drug Development*, **2018**, 3, 83-94	1.6	3
12	Dissecting resistance to endocrine therapy in breast cancer. *Cell Cycle*, **2008**, 7, 1895-8	4.7	3
11	PARP Inhibitors - Trapped in a Toxic Love Affair. *Cancer Research*, **2021**, 81, 5605-5607	10.1	3
10	Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. *Methods in Molecular Biology*, **2018**, 1711, 83-99	1.4	2

9	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
8	Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. *Communications Biology*, **2021**, 4, 1270	6.7	1
7	Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. *Cancers*, **2021**, 13,	6.6	1
6	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
5	Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. *PLoS Genetics*, **2021**, 17, e1009354	6	1
4	Identifying Modifiers of Tamoxifen Sensitivity Using High-Throughput Genetic and Chemical Screens **2009**, 161-174		
3	Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening.. *Journal of Clinical Oncology*, **2014**, 32, 4039-4039	2.2	
2	JAK2 Is a Direct BCL6 Target Gene: Implications for Therapy in Diffuse Large B-Cell Lymphoma. *Blood*, **2014**, 124, 3112-3112	2.2	
1	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 31-31	2.2	